Senzime AB (publ) (SEZI.ST) Stock Analysis & Winston Score

Senzime is a Swedish medical device company that makes monitoring equipment used in hospitals during and after surgery. Its main product is the TetraGraph system, which measures how well a patient's muscles are working after they receive drugs that temporarily paralyze them during an operation. The company sells primarily to hospitals and anesthesia departments across Europe and North America. Senzime earns revenue by selling the TetraGraph monitoring devices as well as single-use sensor electrodes that must be replaced for each patient, creating a recurring consumables revenue stream alongside hardware sales. The company is headquartered in Uppsala, Sweden, and operates at a significant loss, spending far more than it earns as it tries to grow its commercial presence. The key growth driver is wider adoption of neuromuscular monitoring guidelines that recommend routine muscle-function checks after surgery, but the main risk is that the company may need to raise additional capital before it reaches profitability.